{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-077646","form_type":"8-K","ticker":"LRMR","cik":"0001374690","company_name":"Larimar Therapeutics, Inc.","filed_at":"2026-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.939074+00:00","generated_at":"2026-05-15T23:00:19.946413+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Larimar Therapeutics prices 20M share public offering at $5.00 per share; underwriters exercise over-allotment","bullets":["Offering of 20,000,000 shares plus 3,000,000 over-allotment shares at $5.00 per share.","Net proceeds after underwriting discounts and expenses expected to be approx. $107.6M.","Underwriters include J.P. Morgan, Guggenheim, LifeSci Capital, William Blair, and others.","Offering expected to close on February 27, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-077646","json":"https://secwatch.observer/filing/0001193125-26-077646.json","markdown":"https://secwatch.observer/filing/0001193125-26-077646.md","text":"https://secwatch.observer/filing/0001193125-26-077646.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374690/000119312526077646/0001193125-26-077646-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374690/000119312526077646/d120172d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:00:19.946413+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"25602a819e37cb7f08abf1961a3161fd8a61b83a","claim":"Larimar Therapeutics, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC and Guggenheim Securities, LLC valued at 20,000,000 shares at $5.00 per share, option for additional 3,000,000 shares exercised, net proceeds (effective 2026-02-25).","evidence_excerpt":"On February 25, 2026, Larimar Therapeutics, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with J.P. Morgan Securities LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named therein (the “ Underwriters ”), relating to the issuance and sale of an aggregate of 20,000,000 shares (the “ Firm Shares ”) of common stock, par value $0.001 per share (the “ Common Stock ”), of the Company at a public offering price of $5.00 per share (the “ Offering ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1374690/000119312526077646/0001193125-26-077646-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"J.P. Morgan Securities LLC and Guggenheim Securities, LLC"},{"label":"Value","value":"20,000,000 shares at $5.00 per share, option for additional 3,000,000 shares exercised, net proceeds"},{"label":"Effective","value":"2026-02-25"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}